Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.43 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16100512 | 0.89 | CYP4F2 (0.40) | CYP4F2CYP4A11GSK3BCHEK2LRRK2 | |
| SCHEMBL17469482 | 0.86 | PARP15 (0.41) | — | |
| SCHEMBL17469448 | 0.86 | PARP15 (0.42) | — | |
| SCHEMBL17469505 | 0.84 | GSK3B (0.38) | GSK3BLRRK2GRM4 | |
| SCHEMBL17469471 | 0.77 | TTK (0.48) | LRRK2 | |
| SCHEMBL16100520 | 0.77 | CYP4F2 (0.41) | F10CYP4F2CYP4A11GSK3BCHEK2 | |
| SCHEMBL17469501 | 0.76 | FLT3 (0.41) | F10 | |
| SCHEMBL16129427 | 0.76 | PRMT1 (0.47) | LRRK2PRMT5WDR77 | |
| SCHEMBL16102946 | 0.76 | CYP4F2 (0.43) | CYP4F2CYP4A11GSK3BCHEK2LRRK2 | |
| SCHEMBL17469484 | 0.76 | TTK (0.39) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9765035-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | F10 4663/4885CYP4F2 751/4885CYP4A11 765/4885 |
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | F10 4663/4885CYP4F2 751/4885CYP4A11 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.